Aquestive Therapeutics Inc (NASDAQ:AQST) price on current trading day, rose 8.36% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $2.98.
A look at the stock’s price movement, the close in the last trading session was $2.75, moving within a range at $2.76 and $2.99. The beta value (5-Year monthly) was 2.759. Turning to its 52-week performance, $5.80 and $2.24 were the 52-week high and 52-week low respectively. Overall, AQST moved -5.40% over the past month.
Aquestive Therapeutics Inc’s market cap currently stands at around $294.64 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Mar-04.
Analysts have a consensus estimate of 12.23M for the company’s revenue for the quarter, with a low and high estimate of 11.6M and 13M respectively. The average forecast suggests up to a 1.47% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 49.58M, representing a -13.87% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that AQST is a 50% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 3 recommend AQST as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
AQST’s current price about 6.88% and -0.22% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 53.12, while 7-day volatility ratio is 7.23% and 7.55% in the 30-day chart. Further, Aquestive Therapeutics Inc (AQST) has a beta value of 2.62, and an average true range (ATR) of 0.21. Analysts have given the company’s stock an average 52-week price target of $8.5, forecast between a low of $7 and high of $10. Looking at the price targets, the low is -134.9% off current price level while to achieve the yearly target high, price needs to move -235.57%. Nonetheless, investors will most likely welcome a -185.23% jump to $8.5 which is the analysts’ median price.
If we refocus on Aquestive Therapeutics Inc (NASDAQ:AQST), historical trading data shows that trading volumes averaged 1.32 over the past 10 days and 1.62 million over the past 3 months. The company’s latest data on shares outstanding shows there are 91.41 million shares.
The 11.22% of Aquestive Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 38.69% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 9.98 million on 2025-02-28, giving us a short ratio of 4.93. The data shows that as of 2025-02-28 short interest in Aquestive Therapeutics Inc (AQST) stood at 1306.9999 of shares outstanding, with shares short falling to 11.09 million registered in 2025-01-31. Current price change has pushed the stock -16.29% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the AQST stock continues to rise going into the next quarter.
